Skip to main content
. Author manuscript; available in PMC: 2019 Sep 11.
Published in final edited form as: J Am Coll Cardiol. 2018 Sep 11;72(11):1187–1197. doi: 10.1016/j.jacc.2018.05.074

Figure 3. Cumulative incidence of CVD events and all-cause mortality among 15,179 REGARDS study participants taking antihypertensive medication by blood pressure category (top panel) and recommendation for pharmacological antihypertensive treatment intensification (bottom panel).

Figure 3.

ACC: American College of Cardiology; AHA: American Heart Association; CVD: cardiovascular disease; DBP: diastolic blood pressure; REGARDS: REasons for Geographic and Racial Differences in Stroke; SBP: systolic blood pressure.* Blood pressure categories are mutually exclusive. Participants whose SBP and DBP correspond to two separate categories were assigned to the higher blood pressure group† Analyses of the recommendation for antihypertensive medication intensification were restricted to participants with SBP between 130 and 139 mmHg or DBP between 80 and 89 mmHg. Recommendations for antihypertensive medication intensification according to the 2017 ACC/AHA blood pressure guideline are shown in Online Table 2. The median follow-up for CVD events was 7.8 years (maximum 11.8 years). The median follow-up for all-cause mortality was 8.2 years (maximum 11.9 years). On the X-axis, time 0 represents the date of the in-home baseline study visit for each participant.